IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced imm... IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. Show more
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...
Outcome of interim analysis for the overall response rate (ORR) for the first 225 patients randomized in the pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer...
NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.14 | 11.4754098361 | 1.22 | 1.43 | 1.14 | 62184 | 1.19724901 | CS |
4 | 0.11 | 8.8 | 1.25 | 1.43 | 1.02 | 100356 | 1.21338379 | CS |
12 | -0.2 | -12.8205128205 | 1.56 | 1.79 | 1.02 | 102635 | 1.32497308 | CS |
26 | -0.63 | -31.6582914573 | 1.99 | 1.99 | 1.02 | 120947 | 1.52910557 | CS |
52 | -0.51 | -27.2727272727 | 1.87 | 2.18 | 0.8163 | 126591 | 1.49683659 | CS |
156 | -14.64 | -91.5 | 16 | 17.88 | 0.8163 | 99581 | 3.31131025 | CS |
260 | -14.64 | -91.5 | 16 | 17.88 | 0.8163 | 99581 | 3.31131025 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.